Ideas

Using tiny Probiotics to extend the lifespan of mighty humans: Probiotic Clostridium butyricum MIYAIRI 588 (CBM 588) increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 26/February/2019, 8.26 am
Using tiny Probiotics to extend the lifespan of mighty humans: Probiotic Clostridium butyricum MIYAIRI 588 (CBM 588) increases CHIP levels, increases monoubiquitylation of insulin receptor (INSR), decreases INSR protein levels and enhances lifespan, via down regulation of its target gene, 26/February/2019, 8.26 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Institute for Cell Biology, University of Bonn, Ulrich-Haberland Str.  Bonn, Germany; and Institute for Genetics and CECAD Research Center, University of Cologne, Joseph-Stelzmann…

read more

Ribonucleic acid-based Lifespan extension therapy: A therapeutic mix encompassing lncRNA-NEAT1 and/or Melatonin, Ursolic acid, Maresin, DIM, Ursolic acid  Lutein, Maresin, Cholecalciferol, Catalpol, Isoliquiritigenin (MUMDULMCCI) activates autophagy, promotes leanness, increases insulin sensitivity, improves motor function, alleviates ageing feature and extends lifespan via upregulation of its target gene ATG5 (Autophagy-related 5), 26/February/2018, 12.37 am
Ribonucleic acid-based Lifespan extension therapy: A therapeutic mix encompassing lncRNA-NEAT1 and/or Melatonin, Ursolic acid, Maresin, DIM, Ursolic acid  Lutein, Maresin, Cholecalciferol, Catalpol, Isoliquiritigenin (MUMDULMCCI) activates autophagy, promotes leanness, increases insulin sensitivity, improves motor function, alleviates ageing feature and extends lifespan via upregulation of its target gene ATG5 (Autophagy-related 5), 26/February/2018, 12.37 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Global Research Laboratory, Seoul National University, Korea shows that “Overexpression of Atg5 in mice activates autophagy and extends lifespan.” This study was published, in the online…

read more

Lipid-lowering agent Fenofibrate comes to the rescue of glaucoma: Fenofibrate (trade name: Tricor,  Fenacor, Feno-TG, Fenobate, Fenocor, Fenofibric, Fenolip and others), a drug used to lower cholesterol and triglycerides,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 26/February/2019, 12.14 am
Lipid-lowering agent Fenofibrate comes to the rescue of glaucoma: Fenofibrate (trade name: Tricor,  Fenacor, Feno-TG, Fenobate, Fenocor, Fenofibric, Fenolip and others), a drug used to lower cholesterol and triglycerides,  increases Nmnat1 expression, increases NAD+ levels, improves neuronal dysfunction, and protects against glaucoma,  via down regulation of its target gene, 26/February/2019, 12.14 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the The Jackson Laboratory, Bar Harbor, ME 04609, USA; Department of Ophthalmology, Tufts University of Medicine, Boston, MA 02111, USA; The Howard Hughes…

read more

Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA CACS15 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 25/February/2019, 1.34 am
Ribonucleic acid-based therapy for Diabetes Mellitus: LncRNA CACS15 augments the expression of FGF19 and FGF1,  attenuates hepatic glucose production, decreases hepatic acetyl CoA content, brings down the levels of plasma ACTH, and corticosterone, augments insulin sensitivity, promotes weight loss and alleviates TIDM via upregulation of its target gene, 25/February/2019, 1.34 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say  A study from Diabetes and Obesity Center of Excellence, Department of Medicine, University of Washington, Seattle, Washington, USA shows that Central injection of FGF1 induces sustained…

read more

Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Canthardin   and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 25/February/2019, `1.27 am
Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in advanced metastatic cancers: A pharmaceutical mixture encompassing Canthardin   and probiotic Lactobacillus rhamnosus increases the expression of tumor suppressor genes, such as TPM1, TIMP3, p53, and TA-p73/p63, inhibits immune-inhibitory receptors/molecules, targets cancer stem cells, confers protection against chemoresistance and prolongs survival, via up-regulation of its target gene, 25/February/2019, `1.27 am 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: On the foundation of this interesting finding, Dr L Boominathan PhD, the Director-cum-chief Scientist of GBMD, reports that:  Probiotic-based chemotherapy targeting cancer stem cells and immune-inhibitory receptors in…

read more

The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: A therapeutic mix encompassing Metformin, Navitoclax, dasatinib, 2-deoxy-d-glucose (2DG) (MNDDG)  inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 1.17 am
The Ptpn2 pathway blockade enhances the efficacy of Cancer immunotherapy: A therapeutic mix encompassing Metformin, Navitoclax, dasatinib, 2-deoxy-d-glucose (2DG) (MNDDG)  inhibits the expression of protein tyrosine phosphatase PTPN2, increases interferon-IFNγ signaling, augments antigen presentation and unfolding response, increases Cytotoxic activity of T-cells, decreases tumor burden and increases survival, via up-regulation of its target gene, 25/February/2019, 1.17 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA; Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, Massachusetts…

read more
Start Typing